TABLE 1.
Adjuvant effects of VSV-G on Gag-specific CTL response
| Injected DNA (10 μg)a | No. of responding mice/no. tested (%)b | P (χ2 Pearson test) |
|---|---|---|
| pCMV ΔR8-2 + pCMV.VSV (same paws) | 13/28 (46) | <0.001 |
| pCMV ΔR8-2 + pCMV.AS (same paws) | 0/17 (0) | |
| pCMV ΔR8-2 + pCMV.VSV (same paws) | 13/28 (46) | <0.05 |
| pCMV ΔR8-2 + pCMV.VSV mutc (same paws) | 2/14 (14) | |
| pCMV ΔR8-2 and pCMV.VSV (separate paws) | 3/14 (21) | <0.05 |
| pCMV ΔR8-2 + pCMV.AS (same paws) | 0/17 (0) |
a
DNA was injected into normal muscle.
b
Splenocyte cytotoxic activity was measured against P815 target cells pulsed or not pulsed with HIV-1 Gag peptide.
c
VSV mut is a nonfusogenic VSV-G envelope.